Acquired immune and inflammatory myopathies: Pathologic classification

Current Opinion in Rheumatology

Volumn 23, Issue 6, 2011, Pages 595-604

  Pestronk, Alan ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Dermatomyositis; Immune and inflammatory myopathies; Inclusion body myositis; Muscle pathology; Polymyositis

Indexed keywords

ALKALINE PHOSPHATASE; ENDOMYSIUM ANTIBODY; SIGNAL RECOGNITION PARTICLE;

B LYMPHOCYTE; BRACHIOCERVICAL INFLAMMATORY MYOPATHY; CAPILLARY; CELLULAR IMMUNITY; CLINICAL FEATURE; CONNECTIVE TISSUE; DERMATOMYOSITIS; DIAGNOSTIC ACCURACY; DISEASE CLASSIFICATION; HISTIOCYTIC INFLAMMATORY MYOPATHY; HUMAN; HUMORAL IMMUNITY; INCLUSION BODY MYOSITIS; MUSCLE CELL; MYOSITIS; PERIMYSIUM; POLYMYOSITIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; STAINING;

DERMATOMYOSITIS; HISTIOCYTES; HUMANS; MITOCHONDRIA, MUSCLE; MUSCLE FIBERS, SKELETAL; MYOSITIS; MYOSITIS, INCLUSION BODY; POLYMYOSITIS; VACUOLES;

EID: 82955236144     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0b013e32834bab42     Document Type: Review

References (55)

1. Dalakas MC. An update on inflammatory and autoimmune myopathies. Neuropathol Appl Neurobiol 2011; 37:226-242.
2. Hilton-Jones D. Observations on the classification of the inflammatory myopathies. Presse Med 2011; 40:e199-e208.
3. Zong M, Lundberg IE. Pathogenesis, classification and treatment of inflammatory myopathies. Nat Rev Rheumatol 2011; 7:297-306.
4. Khan S, Christopher-Stine L. Polymyositis, dermatomyositis, and autoimmune necrotizing myopathy: clinical features. Rheum Dis Clin North Am 2011; 37:143-158.
5. Gherardi RK. Pathogenic aspects of dermatomyositis, polymyositis and overlap myositis. Presse Med 2011; 40:e209-e218.
6. Sultan SM, Isenberg DA. Re-classifying myositis. Rheumatology (Oxford) 2010; 49:831-833.
7. Miller T, Al-Lozi MT, Lopate G, Pestronk A. Myopathy with antibodies to the signal recognition particle: clinical and pathological features. J Neurol Neurosurg Psychiatry 2002; 73:420-428.
8. Takada T, Hirakata M, Suwa A, et al. Clinical and histopathological features of myopathies in Japanese patients with anti-SRP autoantibodies. Mod Rheumatol 2009; 19:156-164.
9. Levin MI, Mozaffar T, Al-Lozi MT, Pestronk A. Paraneoplastic necrotizing myopathy: clinical and pathological features. Neurology 1998; 50:764-767.
10. Christopher-Stine L, Casciola-Rosen LA, Hong G, et al. A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immunemediated necrotizing myopathy. Arthritis Rheum 2010; 62:2757-2766.
11. Katzap E, Barilla-Labarca ML, Marder G. Antisynthetase syndrome. Curr Rheumatol Rep 2011; 13:175-181.
12. Váncsa A, Gergely L, Ponyi A, et al. Myositis-specific and myositis-associated antibodies in overlap myositis in comparison to primary dermatopolymyositis: relevance for clinical classification: retrospective study of 169 patients. Joint Bone Spine 2010; 77:125-130.
13. Dugar M, Cox S, Limaye V, et al. Clinical heterogeneity and prognostic features of South Australian patients with antisynthetase autoantibodies. Intern Med J 2010.
14. Nozaki K, Pestronk A. High aldolase with normal creatine kinase in serum predicts a myopathy with perimysial pathology. J Neurol Neurosurg Psychiatry 2009; 80:904-908.
15. Pestronk A, Schmidt RE, Choksi R. Vascular pathology in dermatomyositis and anatomic relations to myopathology. Muscle Nerve 2010; 42:53-61.
16. van der Meulen MF, Bronner IM, Hoogendijk JE, et al. Polymyositis: an over diagnosed entity. Neurology 2003; 61:316-321.
17. Ramesha KN, Kuruvilla A, Sarma PS, Radhakrishnan VV. Clinical, electrophysiologic, and histopathologic profile, and outcome in idiopathic inflammatory myositis: an analysis of 68 cases. Ann Indian Acad Neurol 2010; 13:250-256.
18. Temiz P, Weihl CC, Pestronk A. Inflammatory myopathies with mitochondrial pathology and protein aggregates. J Neurol Sci 2009; 278:25-29.
19. Pestronk A. Immune and inflammatory myopathies: pathology. Neuromuscular Disease Center. http://neuromuscular.wustl.edu/antibody/infmyop.htm# pathology. [Accessed June 2011]
20. Pestronk A, Kos K, Lopate G, Al-Lozi MT. Brachio-cervical inflammatory myopathies: clinical, immune, and myopathologic features. Arthritis Rheum 2006; 54:1687-1696.
21. Mozaffar T, Pestronk A. Myopathy with anti-Jo-1 antibodies: pathology in perimysium and neighbouring muscle fibres. J Neurol Neurosurg Psychiatry 2000; 68:472-478. (Pubitemid 30248747)
22. Allen JA, Greenberg SA, Amato AA. Dermatomyositis-like muscle pathology in patients with chronic graft-versus-host disease. Muscle Nerve 2009; 40:643-647.
23. Pestronk A. Fasciitis: pathology. Neuromuscular Disease Center. http://neuromuscular.wustl.edu/pathol/fasciitis.htm. [Accessed June 2011]
24. Varadhachary AS, Weihl CC, Pestronk A. Mitochondrial pathology in immune and inflammatory myopathies. Curr Opin Rheumatol 2010; 22: 651-657.
25. Pestronk A. Immune and inflammatory myopathies: pathology. Neuromuscular Disease Center. http://neuromuscular.wustl.edu/pathol/dermmyo.htm#pffib. [Accessed June 2011]
26. Salajegheh M, Kong SW, Pinkus JL, et al. Interferon-stimulated gene 15 (ISG15) conjugates proteins in dermatomyositis muscle with perifascicular atrophy. Ann Neurol 2010; 67:53-63.
27. Gunawardena H, Wedderburn LR, Chinoy H, et al. Juvenile Dermatomyositis Research Group, UK and Ireland. Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis. Arthritis Rheum 2009; 60:1807-1814.
28. Selva-O'Callaghan A, Fonollosa-Pla V, Trallero-Araguás E, et al. Nailfold capillary microscopy in adults with inflammatory myopathy. Semin Arthritis Rheum 2010; 39:398-404.
29. Krahn M, Lopez de Munain A, Streichenberger N, et al. CAPN3 mutations in patients with idiopathic eosinophilic myositis. Ann Neurol 2006; 59:905-911. (Pubitemid 43830922)
30. Al-Lozi MT, Hemelt VB, Pestronk A. Steroid-responsive myopathy with deficient chondroitin sulfate C in skeletal muscle connective tissue. Neurology 1998; 50:526-529. (Pubitemid 28119807)
31. Yabe I, Kikuchi S, Higashi T, et al. A Japanese case of steroid responsive myopathy with deficient chondroitin sulphate. J Neurol Neurosurg Psychiatry 2002; 73:89-90. (Pubitemid 34713028)
32. Al-Lozi MT, Pestronk A, Choksi R. A skeletal muscle-specific form of decorin is a target antigen for a serum IgM M-protein in a patient with a proximal myopathy. Neurology 1997; 49:1650-1654. (Pubitemid 28015133)
33. Mozaffar T, Lopate G, Pestronk A. Clinical correlates of granulomas in muscle. J Neurol 1998; 245:519-524. (Pubitemid 28398817)
34. Le Roux K, Streichenberger N, Vial C, et al. Granulomatous myositis: a clinical study of thirteen cases. Muscle Nerve 2007; 35:171-177.
35. Israeli E, Agmon-Levin N, Blank M, Shoenfeld Y. Macrophagic myofaciitis: a vaccine (alum) autoimmune-related disease. Clin Rev Allergy Immunol 2010.
36. Bassez G, Authier FJ, Lechapt-Zalcman E, et al. Inflammatory myopathy with abundant macrophages (IMAM): a condition sharing similarities with cytophagic histiocytic panniculitis and distinct from macrophagic myofasciitis. J Neuropathol Exp Neurol 2003; 62:464-474. (Pubitemid 36560188)
37. Brunn A, Hans VJ, Vogelgesang S, Deckert M. Inflammatory myopathy with abundant macrophages and dermatomyositis: two stages of one disorder or two distinct entities? Acta Neuropathol 2009; 118:793-801.
38. Hara S, Henmi T, Kawakami A, et al. Clinical, serologic and magnetic resonance imaging of 3 cases of inflammatory myopathy with abundant macrophages in the Japanese population. Rheumatol Int 2010.
39. Lach B, Cupler EJ. Macrophagic myofasciitis in children is a localized reaction to vaccination. J Child Neurol 2008; 23:614-619. (Pubitemid 351720417)
40. Pestronk A. Dystrophinopathies: Becker. Neuromuscular Disease Center. http://neuromuscular.wustl.edu/pathol/bmdpath.htm.
41. van der Meulen MF, Hoogendijk JE, Moons KG, et al. Rimmed vacuoles and the added value of SMI-31 staining in diagnosing sporadic inclusion body myositis. Neuromuscul Disord 2001; 11:447-451. (Pubitemid 32510004)
42. Weihl CC, Temiz P, Miller SE, et al. TDP-43 accumulation in inclusion body myopathy muscle suggests a common pathogenic mechanism with frontotemporal dementia. J Neurol Neurosurg Psychiatry 2008; 79:1186-1189.
43. Salajegheh M, Pinkus JL, Taylor JP, et al. Sarcoplasmic redistribution of nuclear TDP-43 in inclusion body myositis. Muscle Nerve 2009; 40:19-31.
44. Mendell JR, Sahenk Z, Gales T, Paul L. Amyloid filaments in inclusion body myositis. Novel findings provide insight into nature of filaments. Arch Neurol 1991; 48:1229-1234.
45. Banwell BL, Engel AG. AlphaB-crystallin immunolocalization yields new insights into inclusion body myositis. Neurology 2000; 54:1033-1041. (Pubitemid 30151842)
46. Askanas V, Engel WK. Sporadic inclusion-body myositis: conformational multifactorial ageing-related degenerative muscle disease associated with proteasomal and lysosomal inhibition, endoplasmic reticulum stress, and accumulation of amyloid-b42 oligomers and phosphorylated tau. Presse Med 2011; 40:e219-e235.
47. Blume G, Pestronk A, Frank B, Johns DR. Polymyositis with cytochrome oxidase negative muscle fibres. Early quadriceps weakness and poor response to immunosuppressive therapy. Brain 1997; 120:39-45. (Pubitemid 27081259)
48. Santorelli FM, Sciacco M, Tanji K, et al. Multiple mitochondrial DNA deletions in sporadic inclusion body myositis: a study of 56 patients. Ann Neurol 1996; 39:789-795. (Pubitemid 26183815)
49. Greenberg SA, Pinkus JL, Amato AA. Nuclear membrane proteins are present within rimmed vacuoles in inclusion-body myositis. Muscle Nerve 2006; 34:406-416. (Pubitemid 44506707)
50. Lotz BP, Engel AG, Nishino H, et al. Inclusion body myositis. Observations in 40 patients. Brain 1989; 112:727-747. (Pubitemid 19151167)
51. Amato AA, Gronseth GS, Jackson CE, et al. Inclusion body myositis: clinical and pathological boundaries. Ann Neurol 1996; 40:581-586. (Pubitemid 26357882)
52. Cox FM, Reijnierse M, van Rijswijk CS, et al. Magnetic resonance imaging of skeletal muscles in sporadic inclusion body myositis. Rheumatology (Oxford) 2011; 50:1153-1161.
53. Zampieri S, Valente M, Adami N, et al. Polymyositis, dermatomyositis and malignancy: a further intriguing link. Autoimmun Rev 2010; 9:449-453.
54. Kaji K, Fujimoto M, Hasegawa M, et al. Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy. Rheumatology (Oxford) 2007; 46:25-28. (Pubitemid 44932779)
55. Trallero-Araguás E, Labrador-Horrillo M, Selva-O'Callaghan A, et al.Cancerassociated myositis and antip155 autoantibody in a series of 85 patients with idiopathic inflammatory myopathy. Medicine (Baltimore) 2010; 89: 47-52.